BPC-157

Overview

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a larger protein called Body Protection Compound (BPC), which is naturally found in human gastric juice. First isolated and characterized in the early 1990s by Professor Predrag Sikiric and colleagues at the University of Zagreb, Croatia, BPC-157 has been the subject of extensive preclinical research spanning over three decades.

The peptide's name reflects its origin: it is a protective compound identified in the body's own gastrointestinal secretions. In its native environment, BPC plays a role in maintaining the integrity of the gastrointestinal tract. The synthetic fragment BPC-157 retains and, in many cases, amplifies these protective properties.

What makes BPC-157 particularly noteworthy in the peptide research community is the sheer breadth of its studied effects. Unlike many peptides that act through a single, well-defined receptor pathway, BPC-157 appears to modulate multiple biological systems simultaneously — a characteristic that has led to its description as a "pleiotropic" peptide.

As of 2026, BPC-157 has limited human data. It entered clinical trials for inflammatory bowel disease in Croatia under Pliva Pharmaceuticals (designated PL-10, PLD-116, PL14736), and a 2025 pilot study demonstrated safety of intravenous administration in two adults at doses up to 20 mg. A small retrospective study (n=12) reported intraarticular knee injection results. However, the vast majority of published data comes from rodent studies, primarily from research groups in Croatia.

Amino Acid Sequence

BPC-157's primary sequence consists of 15 amino acids:

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

• Molecular formula: C₆₂H₉₈N₁₆O₂₂
• Molecular weight: 1,419.53 g/mol
• CAS Number: 137525-51-0

The peptide is typically available in two salt forms:

• BPC-157 acetate — the more common commercially available form
• BPC-157 arginate — a salt form that some researchers suggest may have improved oral bioavailability

Mechanism of Action

BPC-157's mechanisms are multifaceted and not yet fully elucidated. Research suggests it acts through several interconnected pathways:

Nitric Oxide (NO) System Modulation

BPC-157 appears to interact bidirectionally with the nitric oxide system. Studies have shown it can counteract both NO-synthase (NOS) inhibitor-induced effects and NO-system overstimulation. This dual modulatory capacity is unusual among peptides and may explain its observed effects across diverse tissue types.

The peptide has been observed to maintain NO homeostasis, which is critical for:

• Blood vessel dilation and formation
• Inflammation regulation
• Neurotransmission
• Gastrointestinal motility

Angiogenesis Promotion

Multiple studies have documented BPC-157's ability to accelerate the formation of new blood vessels (angiogenesis). This is mediated through:

• Upregulation of vascular endothelial growth factor (VEGF) expression
• Activation of the VEGFR2 signaling pathway
• Enhancement of collateral vessel formation in ischemic tissue

The angiogenic properties are considered central to BPC-157's tissue repair capabilities, as new blood supply is essential for healing in virtually all tissue types.

FAK-Paxillin Pathway Activation

BPC-157 has been shown to activate the FAK-paxillin pathway. This pathway is critical for:

• Cell migration toward injury sites
• Cell survival and anti-apoptotic signaling
• Cytoskeletal reorganization during tissue remodeling
• Wound closure acceleration

Growth Factor Modulation

Research has documented BPC-157's interactions with several growth factor systems:

• EGF (Epidermal Growth Factor) — enhanced EGF receptor expression in intestinal tissue
• FGF (Fibroblast Growth Factor) — upregulation in tendon and ligament healing studies
• HGF (Hepatocyte Growth Factor) — implicated in BPC-157's liver-protective effects
• TGF-beta — modulation observed in wound healing contexts

Dopamine System Interactions

BPC-157 has demonstrated interactions with the dopaminergic system in multiple studies:

• Counteraction of dopamine-related behavioral disturbances in animal models
• Potential modulation of dopamine receptor sensitivity
• Interactions with the dopamine-serotonin systems

Growth Hormone Receptor (GHR) Upregulation

BPC-157 upregulates Growth Hormone Receptor expression in tendon fibroblasts at both the mRNA and protein levels in a dose- and time-dependent manner (Chang et al., 2014). This sensitizes local tissue to circulating GH, amplifying proliferation-promoting effects of endogenous growth hormone at injury sites.

Early Growth Response Gene-1 (Egr-1) Activation

BPC-157 rapidly upregulates Egr-1, a transcription factor that acts as a master switch for genes involved in cell growth, survival, angiogenesis, and extracellular matrix production. Within 2–10 minutes of wound induction, BPC-157 increases expression of Akt1, Nos3, Egr1, Vegfa, and Kras in coordinated sequential patterns.

JAK-2/STAT Signaling

BPC-157 stimulates JAK-2/STAT signaling (Janus Kinase 2), a non-receptor tyrosine kinase involved in cytokine receptor signaling, cell survival, and immune regulation.

Cytoprotective Effects

The peptide has shown protective effects against a wide range of toxic insults in animal studies, including:

• Alcohol-induced gastric lesions
• NSAID-induced gastrointestinal damage (through prostaglandin-independent pathways)
• Various hepatotoxins
• Potassium overload-induced arrhythmias
• Doxorubicin-induced cardiomyopathy

Research Summary

The following table summarizes key published studies on BPC-157. All data is from preclinical (animal) research unless otherwise noted:

Area of Study	Key Finding	Notable Reference
Tendon healing	Accelerated Achilles tendon healing in rats; increased collagen organization and mechanical strength	Staresinic et al., Journal of Orthopaedic Research, 2003
Muscle healing	Enhanced muscle healing after crush injury; improved functional recovery in rats	Pevec et al., Journal of Physiology and Pharmacology, 2010
Bone healing	Accelerated bone fracture healing in rabbits; improved callus formation	Sebecic et al., Journal of Orthopaedic Research, 1999
Ligament repair	Promoted medial collateral ligament healing in rats	Chang et al., Journal of Applied Physiology, 2011
Gastrointestinal	Protected against ethanol, NSAID, and stress-induced gastric lesions in rats	Sikiric et al., Journal of Physiology-Paris, 1999
Inflammatory bowel	Ameliorated colitis in multiple animal models	Veljaca et al., Journal of Pharmacology and Experimental Therapeutics, 2003
Liver protection	Counteracted hepatotoxicity from alcohol and various hepatotoxins	Ilic et al., Life Sciences, 2011
Brain injury	Neuroprotective effects in traumatic brain injury models; improved functional outcomes	Tudor et al., Journal of Physiology and Pharmacology, 2010
Peripheral nerve	Accelerated sciatic nerve repair after transection in rats	Gjurasin et al., Digestive Diseases and Sciences, 2007
Corneal healing	Enhanced corneal wound healing in rabbit models	Lazarov et al., Investigative Ophthalmology & Visual Science, 2005
Burns	Accelerated burn wound healing; improved re-epithelialization	Mikus et al., Journal of Physiology and Pharmacology, 2001
Angiogenesis	Promoted new blood vessel formation in chicken chorioallantoic membrane assay and rat ischemic models	Sikiric et al., Current Pharmaceutical Design, 2018
Dopamine system	Counteracted neuroleptic-induced catalepsy; modulated amphetamine and apomorphine effects	Sikiric et al., European Journal of Pharmacology, 2010
Alcohol withdrawal	Reduced alcohol withdrawal symptoms in rats	Jelovac et al., Alcohol and Alcoholism, 1999
Fistula healing	Successful simultaneous healing of esophagocutaneous, gastrocutaneous, colocutaneous, and rectovaginal fistulas	Sikiric et al., Current Pharmaceutical Design, 2020
VEGFR2 activation	Direct evidence of VEGFR2 pathway involvement and increased vascular density	Hsieh et al., Journal of Applied Physiology, 2017
GH receptor	Upregulated growth hormone receptor expression in tendon fibroblasts (dose- and time-dependent)	Chang et al., Molecules, 2014
Pharmacokinetics	First formal PK study: t½ < 30 min; linear PK; IM bioavailability 14–51% across species	Frontiers in Pharmacology, 2022
Systematic review	36 studies analyzed (35 preclinical, 1 clinical); confirmed improvements across tendon, muscle, ligament, and bone models	Vasireddi et al., HSS Journal, 2025
Human safety (IV)	Two adults tolerated up to 20 mg IV with no adverse effects reported	Pilot Study, 2025

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for research peptides. Always consult a qualified healthcare professional.

Standard Subcutaneous Protocol

Phase	Daily Dose	Frequency	Duration
Initiation	200–250 mcg	Once daily	Weeks 1–2
Standard	300–500 mcg	Once daily	Weeks 3–8
Extended	500–600 mcg	Once daily	Weeks 9–12+

Reconstitution (10 mg vial)

• Add 3.0 mL bacteriostatic water → 3.33 mg/mL concentration
• At this concentration: 1 unit = 33.3 mcg on a U-100 insulin syringe
• 250 mcg = ~7.5 units | 500 mcg = ~15 units

Cycle Guidelines

• Cycle length: 8–12 weeks (can extend to 16 weeks)
• Injection timing: Once daily, preferably morning or split into two doses 12 hours apart
• Injection site: Subcutaneous, near the area of concern when possible
• Oral option: 500–1000 mcg daily for GI-specific applications (BPC-157 is uniquely stable in gastric acid)

Supply Estimate (12-week cycle at 500 mcg/day)

• ~4–5 vials (10 mg each)
• 84 insulin syringes
• 15 mL bacteriostatic water

Route of Administration

BPC-157 is notable among peptides for its potential activity through multiple routes:

Subcutaneous Injection

The most common research administration method. Provides systemic distribution with good bioavailability. See Subcutaneous Injection for technique details.

Oral Administration

Unusually for a peptide, BPC-157 has demonstrated biological activity when administered orally in animal studies. This is attributed to:

• Inherent stability in gastric acid (derived from a gastric protein)
• Possible resistance to proteolytic degradation
• Activity at gastrointestinal receptor sites

This oral stability makes BPC-157 unique among research peptides and is particularly relevant for GI-related applications.

Topical/Local Application

Some studies have applied BPC-157 directly to wound sites or as a topical cream. Local application may be particularly relevant for superficial wounds and skin healing.

Pharmacokinetics

A formal pharmacokinetic study was published in 2022 (Frontiers in Pharmacology, PMC9794587), providing the first detailed PK characterization in rats and dogs:

• Elimination half-life: Under 30 minutes (significantly shorter than earlier community estimates of ~4 hours, which were based on duration of biological effect rather than plasma concentration)
• Pharmacokinetics: Linear across studied dose ranges
• Intramuscular bioavailability: 14–19% in rats; 45–51% in dogs
• Urinary excretion: Detectable for up to 4 days post-administration
• Stability: Remarkably stable in human gastric juice for over 24 hours — does not degrade in acidic conditions that would destroy most peptides. This stability is attributed to the three consecutive proline residues (positions 3–5) which confer structural rigidity and protease resistance
• Distribution: Appears to concentrate at sites of injury ("homing" behavior observed in some studies)

Important note: The short plasma half-life does not necessarily reflect the duration of biological effect. BPC-157 triggers downstream signaling cascades (VEGFR2, FAK-paxillin, Egr-1 transcription) that persist well beyond the peptide's clearance from plasma.

Reconstitution and Storage

BPC-157 is supplied as a lyophilized (freeze-dried) white powder:

• Reconstitution solvent: Bacteriostatic water (preferred) or sterile water
• Storage (lyophilized): -20°C for long-term; 2–8°C for weeks
• Storage (reconstituted): 2–8°C, use within 3–4 weeks with bacteriostatic water
• Light sensitivity: Store away from direct light
• Typical vial sizes: 5 mg and 10 mg

For detailed reconstitution instructions, see Peptide Reconstitution.

Common Discussion Topics

Within the research and biohacking community, BPC-157 is frequently discussed in the context of:

1. Injury recovery — Its potential to accelerate healing of tendons, ligaments, muscles, and connective tissue injuries
2. Gut health — Applications related to inflammatory bowel conditions, leaky gut, and NSAID-related GI damage
3. Stacking with TB-500 — Often discussed in combination with TB-500 for synergistic healing effects
4. Neuroprotective applications — Growing interest in its dopaminergic system interactions and brain injury research
5. Oral vs. injectable — Debate over the efficacy of oral capsule forms versus injection
6. Local vs. systemic injection — Whether injecting near an injury site provides superior results

Safety Profile in Animal Studies

In the published preclinical literature:

• No reported lethal dose (LD1) has been established — standard toxicology studies have not identified a lethal dose in rodent models
• No reported organ toxicity at studied doses
• No reported interactions with the HPA axis (hypothalamic-pituitary-adrenal axis)
• No observed mutagenic potential
• No observed tumor-promoting activity

Important caveat: These safety observations come from animal studies. No large-scale human safety trials have been published.

Limitations of Current Research

Despite the extensive body of preclinical research, several significant limitations should be noted:

1. No completed human clinical trials — Almost all data comes from rodent models
2. Research concentration — A disproportionate number of studies originate from a single research group (Sikiric et al., Zagreb)
3. Mechanism complexity — The pleiotropic nature of BPC-157's effects makes it difficult to establish clear cause-and-effect relationships
4. Commercial availability concerns — Quality and purity of commercially available BPC-157 varies significantly between suppliers
5. Regulatory status — Not approved by any regulatory agency for clinical use; research-use only

Related Compounds

• TB-500 (Thymosin Beta-4) — another peptide studied for tissue repair; often discussed in combination with BPC-157
• GHK-Cu (Copper peptide) — studied for wound healing and skin regeneration
• Pentosan Polysulfate (PPS) — a non-peptide compound studied for joint and connective tissue support
• KPV — an anti-inflammatory tripeptide derived from alpha-MSH